---
schema_version: "secwatch.filing_event.v1"
accession: "0001387131-23-008595"
form_type: "8-K"
ticker: null
cik: "0000887247"
company_name: "DMK PHARMACEUTICALS Corp"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:41:20.277118+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CFO David Benedicto resigns; President/COO Marguglio named interim CFO

## Summary
- David C. Benedicto resigned as CFO and principal accounting officer, effective July 21, 2023.
- Resignation not due to any disagreement with the company or auditors on financial matters.
- David J. Marguglio, President and COO, appointed interim CFO while a permanent replacement is sought.
- Marguglio has been with Adamis since 2009 and previously served as CEO until the DMK merger in May 2023.
- Company will commence a search for a new CFO; no formal arrangement or understanding with Mr. Marguglio.

## SEC filing metadata
- accession: 0001387131-23-008595
- form_type: 8-K
- cik: 0000887247
- company_name: DMK PHARMACEUTICALS Corp
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/admp-8k_071823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001387131-23-008595
- JSON: https://secwatch.observer/filing/0001387131-23-008595.json
- Plain text: https://secwatch.observer/filing/0001387131-23-008595.txt

## Key facts
- Executive change
  David C. Benedicto resigned as chief financial officer and principal accounting officer at DMK PHARMACEUTICALS Corp.
  - Action: resigned
  - Role: chief financial officer and principal accounting officer
  source text: On July 18, 2023, David C. Benedicto, the chief financial officer and principal accounting officer of Adamis Pharmaceuticals Corporation (the “Company”), notified the Company that he was tendering his resignation from the Company effective July 21, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm
- Executive change
  David J. Marguglio was appointed as interim chief financial officer at DMK PHARMACEUTICALS Corp.
  - Action: appointed
  - Role: interim chief financial officer
  source text: In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the Company appoints a successor, and the board of directors of the Company has approved that appointment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/887247/000138713123008595/0001387131-23-008595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.